Saturday, May 31, 2025

Latest

Cognetivity: Echelon Raises Price Target To $1.50 After Biogen Approval

Monday was a very big day for companies who are in the business to help patients who suffer from Alzheimer’s, and it was an even bigger day for those patients. On Monday, the long-awaited FDA decision on Biogen’s Aduhelm drug was announced. The FDA approved the treatment, which costs the patient $56,000 per year.

This has sent the shares of companies who are in the field soaring, with Eli Lilly touching all-time highs, gaining about $32 billion on the day. That is more than the roughly $21 billion Biogen gained in market capitalization on the news. Cognetivity Neurosciences also jumped 19% before opening at an all-time high.

Off the back of this news, Echelon Capital Markets almost doubled their 12-month price target on Cognetivity Neurosciences (CSE: CGN) to C$1.50, up from C$0.85 prior, and reiterated their speculative buy rating on the company. Their analyst Stefan Quenneville says that the approval is a major catalyst for Cognetivity. He acknowledges that the FDA’s decision was a controversial outcome but nonetheless says, “it is clearly a major positive catalyst for Cognetivity as we anticipate that potential demand for its Integrated Cognitive Assessment (ICA) platform will likely increase meaningfully as millions of patients will need to be triaged for their suitability for aducanumab.”

The thesis is quite simple and Quenneville explains it perfectly by saying, “Currently, many patients are not properly screened due to limitations with legacy pen and paper-based or computerized tests.” With Biogen’s drug, it is specifically to help people who are affected by early-onset Alzheimer’s, while Cognetivity’s ICA is “a very elegant solution that provides initial diagnosis and ongoing monitoring of a patient’s cognitive ability quickly and accurately.”

Quenneville believes that Cognetivity’s ICA will be approved for use in the U.S by the end of the year, it is currently approved in the UK and EU. Much of the price target increase can be attributed to their increase in the adoption rate of ICA by 20% which you can find below.


FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply

Video Articles

Alamos Gold Q1 Earnings: The Inside Scoop

Cerrado Gold Q4 Earnings: The Turnaround is Working

B2GOLD Q1 Earnings: Revenue Up, Production & Cash Flow Decline

Recommended

Canadian Copper: The $172M Combined Strategy PEA

ESGold Begins Concentration Tests Ahead Of First Production

Related News

Alamos Gold: Canaccord Lifts Target To $13 On Phase 3+ Expansion Study Results

Alamos Gold Inc. (TSX: AGI) announced their phase 3+ expansion study of Island Gold located...

Saturday, July 2, 2022, 01:20:00 PM

Tilray: Canaccord Cuts Price Target To $12 After Q1 Results

On October 7, Tilray Inc (TSX: TLRY) reported their first quarter financial results for the...

Tuesday, October 12, 2021, 10:17:00 AM

Lundin Gold: Canaccord Says Fruta Del Norte Mine Ranks Among Best In World

Lundin Gold Inc. (TSX: LUG) on Tuesday provided investors with a three-year outlook. The company...

Friday, December 2, 2022, 12:36:00 PM

PI Financial Discontinues Coverage On Medipharm Labs, Heritage Cannabis

Friday evening following the close of markets, a note was sent out by PI Financials...

Monday, September 28, 2020, 07:42:00 AM

Facebook: BMO Anticipates Several Headwinds To Hit Top Line

On October 25th, Facebook (NASDAQ: FB), now called Meta Platforms, reported their 2021 third quarter...

Monday, November 1, 2021, 02:56:00 PM